Efficacy and Safety of Topical Rosuvastatin and Melatonin vs. Placebo in Patients with Mild to Moderate Plaque Psoriasis: A Preliminary Randomized Double-Blinded Clinical Trial

This randomized, double-blind clinical trial involving 77 patients with mild to moderate plaque psoriasis found that topical rosuvastatin and melatonin creams significantly reduced the severity of psoriasis compared to a placebo. Over 60 days, both treatments improved Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Disease Severity Score (DSS) without significant adverse effects. Melatonin cream showed a 51% reduction in PASI and a 61% reduction in DSS, while rosuvastatin cream showed a 70% reduction in PASI and a 73% reduction in DSS. These results suggest that both treatments are effective and safe, though larger trials are needed for confirmation.